(Q36723844)

15 August 2017

1 reference

title

Treatment and dosing of Helicobacter pylori infection: when pharmacology meets clinic (English)

1 reference

Helicobacter pylori infectious disease

15 August 2017

1 reference

1 reference

2

Peter Malfertheiner

1 reference

15 August 2017

Gerhard Treiber

1

1 reference

15 August 2017

Ulrich Klotz

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 February 2007

1 reference

Expert Opinion on Pharmacotherapy

15 August 2017

published in

1 reference

15 August 2017

volume

8

1 reference

15 August 2017

issue

3

1 reference

15 August 2017

page(s)

329-350

1 reference

Helicobacter pyloriInfection

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Interleukin-1 polymorphisms associated with increased risk of gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Review article: clinical aspects of Helicobacter pylori eradication therapy in peptic ulcer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Helicobacter pylori-related disease: guidelines for testing and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Helicobacter pylori infection and the development of gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Meta-analysis of the relationship between cagA seropositivity and gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Helicobacter pylori outer membrane proteins and gastroduodenal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

The time to eradicate gastric cancer is now

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Helicobacter pylori vaccine development: facing the challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

The design of vaccines against Helicobacter pylori and their development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

The translation of Helicobacter pylori basic research to patient care

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Novel therapeutic targets in Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Drug delivery strategies for the treatment of Helicobacter pylori infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Pharmacokinetic considerations in the eradication of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Pharmacogenomics of proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

CYP2C19 polymorphism and proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

The role of antisecretory drugs in the treatment of Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Impact of acid secretion, gastritis, and mucus thickness on gastric transfer of antibiotics in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Is eradication of Helicobacter pylori with colloidal bismuth subcitrate quadruple therapy safe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Review article: safety of bismuth in the treatment of gastrointestinal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Stable amoxicillin resistance in Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Gastric juice, gastric tissue and blood antibiotic concentrations following omeprazole, amoxicillin and clarithromycin triple therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Local gastric and serum amoxicillin concentrations after different oral application forms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Amoxicillin and ampicillin are not transferred to gastric juice irrespective of Helicobacter pylori status or acid blockade by omeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Pharmacokinetic and pharmacodynamic interactions between omeprazole and amoxycillin in Helicobacter pylori-positive healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Resistance of Helicobacter pylori to antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Ranitidine bismuth citrate can help to overcome Helicobacter pylori resistance to clarithromycin in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Clarithromycin and omeprazole as helicobacter pylori eradication therapy in patients with H. pylori-associated gastric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Resistance of Helicobacter pylori to antibiotics and its impact on treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

DNA sequence analysis of rdxA and frxA from 12 pairs of metronidazole-sensitive and -resistant clinical Helicobacter pylori isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Tinidazole: from protozoa to Helicobacter pylori--the past, present and future of a nitroimidazole with peculiarities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Effects of food and formulation on the relative bioavailability of bismuth biskalcitrate, metronidazole, and tetracycline given for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Secretion of intravenously administered antibiotics in gastric juice: implications for management of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Alternative and rescue treatment regimens for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Macrolide antibacterials. Drug interactions of clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Empirical Helicobacter pylori "rescue" therapy after failure of two eradication treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Helicobacter pylori "rescue" therapy after failure of two eradication treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Update on Therapeutic Options for Helicobacter pylori-related Diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Effect of acid secretion blockade by omeprazole on the relative bioavailability of orally administered furazolidone in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Furazolidone-based triple 'rescue therapy' vs. quadruple 'rescue therapy' for the eradication of Helicobacter pylori resistant to metronidazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Basis for the management of drug-resistant Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Levofloxacin: a review of its use in the treatment of bacterial infections in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Tetracycline-resistant clinical Helicobacter pylori isolates with and without mutations in 16S rRNA-encoding genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Treatment failures and secondary resistance to antibiotics. A growing concern in Helicobacter pylori therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Rapid detection of point mutations in the gyrA gene of Helicobacter pylori conferring resistance to ciprofloxacin by a fluorescence resonance energy transfer-based real-time PCR approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Antibiotic resistance in Helicobacter pylori: implications for therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Antibiotic resistance mechanisms of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

A systematic review of Helicobacter pylori eradication therapy--the impact of antimicrobial resistance on eradication rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Treatment after failure: the problem of "non-responders".

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Implications of antibiotic resistance in the management of Helicobacter pylori infection: Canadian Helicobacter Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

H pylori antibiotic resistance: prevalence, importance, and advances in testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta‐analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Systematic review and meta-analysis: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Meta-analysis: the influence of pre-treatment with a proton pump inhibitor on Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Systematic review and meta-analysis: importance of CagA status for successful eradication of Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Furazolidone versus metronidazole in quadruple therapy for eradication of Helicobacter pylori in duodenal ulcer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.329

Eradication of Helicobacter pylori for non-ulcer dyspepsia

21 January 2018

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD002096.PUB2

Identifiers

DOI

10.1517/14656566.8.3.329

1 reference

15 August 2017

1 reference